Activity of nadifloxacin and three other antimicrobial agents against Cutibacterium acnes isolated from patients with acne vulgaris
| Autor: | C. Neumeister, Claudia Borelli, M.R. Götz, Rolf-Hasso Bödeker, Constanze Krüger, Pietro Nenoff, U. Schwantes, Daniela Koch |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Tetracycline Erythromycin Microbial Sensitivity Tests Dermatology Skin infection 030207 dermatology & venereal diseases 03 medical and health sciences Propionibacterium acnes chemistry.chemical_compound 0302 clinical medicine Anti-Infective Agents Acne Vulgaris Humans Medicine Letters to the Editor Acne biology business.industry Clindamycin biology.organism_classification medicine.disease Antimicrobial Letter To The Editor Anti-Bacterial Agents Infectious Diseases chemistry Nadifloxacin business Quinolizines Fluoroquinolones medicine.drug |
| Zdroj: | Journal of the European Academy of Dermatology and Venereology |
| ISSN: | 1468-3083 0926-9959 |
| Popis: | Nadifloxacin (OPC-7251) represents an established antimicrobial agent belonging to the quinolone group and was developed exclusively for topical administration. Nadifloxacin is effective in treating a variety of bacterial skin infections and acne. Here, the in vitro activity of nadifloxacin was assessed and compared with those of erythromycin, clindamycin and tetracycline against Cutibacterium (C.) acnes, formerly Propionibacterium acnes, to gain a picture of the resistance situation in Germany. The study was approved by the Ethics Committee of the Bayerische Landesarztekammer (Munich, Germany; EC-No.17088) and registered at Deutsches Register Klinische Studien (ID:DRKS00014231). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text